New oral antithrombotics: A need for laboratory monitoring. Against

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 4, 2010, Pages 627-630

  Bounameaux, H ^a   Reber, G ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETRIXABAN; CYCLOSPORIN; DABIGATRAN ETEXILATE; DIGOXIN; FONDAPARINUX; HEPARIN; KETOCONAZOLE; LITHIUM; LOW MOLECULAR WEIGHT HEPARIN; PENICILLIN G; PHENPROCOUMON; QUINIDINE; RITONAVIR; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; EMBOLISM; FOOD DRUG INTERACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STROKE; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; VITAMIN K; WARFARIN;

EID: 77952733400     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03759.x     Document Type: Article

References (20)

1. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972, 287:324-7.
2. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:141S-59S.
3. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin necessary. No. J Thromb Haemost 2004, 2:551-4.
4. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin necessary. Yes. J Thromb Haemost 2004, 2:547-50.
5. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin-K antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:160S-98S.
6. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:234-S.
7. Gawoski JM, Arkin CF, Bovill T, Brandt J, Rock WA, Triplett DA. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects. Arch Pathol Lab Med 1987, 111:785-90.
8. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the APTT: time for a fresh look. Thromb Haemost 2006, 96:547-52.
9. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kehr A, Aiach M, Fiessinger JM. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994, 71:698-702.
10. Oldenburg J, Watzka M, Rost S, Müller CR. VKORC1: molecular target of coumarins. J Thromb Haemost 2007, 5(Suppl.1):1-6.
11. Schulman S. Clinical practice. Care of patient receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675-83.
12. Haas S. New anticoagulants - towards the development of an " ideal" anticoagulant. Vasa 2009, 38:13-29.
13. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009, 91:636-44.
14. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. J Thromb Haemost 2009, 101:77-85.
15. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Mühlhofer E, Dierig C, Misselwitz F, Kälebo P. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006, 114:2374-81.
16. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-51.
17. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of venous thromboembolism. N Engl J Med 2009, 361:2342-52.
18. Lu G, Luan P, Hollenbach SJ, Abe K, DeGuzman FR, Siu G, Hutchaleelaha A, Inagaki M, Conley PB, Philips DR, Sinha U. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 2009, 7(Suppl.2). abstract-OC-TH-
19. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005, 61:873-80.
20. Stangier J, Wetzel K, Wienen W, van Ryn J, Rathgen K. Measurement of the pharmacodynamic effect of daboigatran etexilate: thrombin clotting time. J Thromb Haemost 2009, 7(Suppl.2). Abstract PP-TH-